MX2018004019A - Formulacion novedosa y metodos de tratamiento. - Google Patents

Formulacion novedosa y metodos de tratamiento.

Info

Publication number
MX2018004019A
MX2018004019A MX2018004019A MX2018004019A MX2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A
Authority
MX
Mexico
Prior art keywords
treatment methods
novel formulation
distal
methods
intestine
Prior art date
Application number
MX2018004019A
Other languages
English (en)
Inventor
Florin Timothy
Popat Amirali
Jambhrunkar Siddharth
Original Assignee
ProdrugXtend Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903951A external-priority patent/AU2015903951A0/en
Application filed by ProdrugXtend Pty Ltd filed Critical ProdrugXtend Pty Ltd
Publication of MX2018004019A publication Critical patent/MX2018004019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona con composiciones farmacéuticas que comprenden 6-tioguanidina (6-TG) en donde la composición está formulada para la liberación de 6-TG en el intestino distal. Métodos para tratar una enfermedad o padecimiento del íleon distal que responden a 6-TG en donde la 6-TG se libera en el intestino distal también se divulgan.
MX2018004019A 2015-09-29 2016-09-29 Formulacion novedosa y metodos de tratamiento. MX2018004019A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903951A AU2015903951A0 (en) 2015-09-29 Novel formulation and treatment methods
AU2016901896A AU2016901896A0 (en) 2016-05-20 Novel formulation and treatment methods
PCT/AU2016/050910 WO2017054042A1 (en) 2015-09-29 2016-09-29 Novel formulation and treatment methods

Publications (1)

Publication Number Publication Date
MX2018004019A true MX2018004019A (es) 2018-09-06

Family

ID=58422496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004019A MX2018004019A (es) 2015-09-29 2016-09-29 Formulacion novedosa y metodos de tratamiento.

Country Status (9)

Country Link
US (2) US11077112B2 (es)
EP (1) EP3359158A4 (es)
CN (1) CN108289894A (es)
AU (1) AU2016333150B2 (es)
BR (1) BR112018006279A2 (es)
CA (1) CA3038602C (es)
MX (1) MX2018004019A (es)
WO (1) WO2017054042A1 (es)
ZA (1) ZA201802201B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023240012A1 (en) * 2022-03-25 2024-10-10 Douglas Pharmaceuticals Ltd Improved thiopurine formulation and treatment methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US5691343A (en) 1995-03-30 1997-11-25 Mayo Foundation For Medical Education And Research Use of topical azathioprine to treat inflammatory bowel disorders
ES2194203T3 (es) 1996-06-19 2003-11-16 Regeneron Pharma Ligando del receptor tie-2 (ligando-4 de tie) y su uso.
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
DE10058772A1 (de) 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
US8188067B2 (en) * 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
EP1845948A2 (en) 2005-02-09 2007-10-24 DA Volterra Colonic delivery of active agents
EP2098236A1 (en) 2008-03-03 2009-09-09 Medizinische Hochschule Hannover Cytostatic compositions
WO2009128955A1 (en) 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Treatment of inflammatory bowel disease with 6-mercaptopurine
WO2010065751A2 (en) * 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130005749A1 (en) * 2011-06-10 2013-01-03 The University Of Queensland Novel formulation and treatment methods
GB2494439A (en) * 2011-09-09 2013-03-13 Nova Bio Pharma Technologies Ltd 6-Mercaptopurine oral suspension for the treatment of acute lymphoblastic leukaemia
EP3362053A4 (en) * 2015-10-16 2019-04-17 Hadasit Medical Research Services and Development Ltd. TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE

Also Published As

Publication number Publication date
EP3359158A1 (en) 2018-08-15
WO2017054042A1 (en) 2017-04-06
CA3038602C (en) 2023-12-05
ZA201802201B (en) 2021-07-28
US20210393638A1 (en) 2021-12-23
US20180235972A1 (en) 2018-08-23
CN108289894A (zh) 2018-07-17
CA3038602A1 (en) 2017-04-06
US12109214B2 (en) 2024-10-08
BR112018006279A2 (pt) 2018-10-16
EP3359158A4 (en) 2019-05-08
AU2016333150A1 (en) 2018-03-29
AU2016333150B2 (en) 2021-12-16
US11077112B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
IN2013MU03373A (es)
BR112017009510A2 (pt) composições compreendendo ciclosporina
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX2018004019A (es) Formulacion novedosa y metodos de tratamiento.
IL261779B (en) Preparations for the treatment and prevention of hoof and claw disease
WO2019022602A8 (en) Pharmaceutical composition for use in the treatment or prevention of vitamin deficiency and mineral deficiency in patients who have been subjected to gastric sleeve surgery
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2019001190A (es) Composicion de liberacion sostenida que comprende tolcapona micronizada.
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
IL247369A0 (en) Compounds and methods for the treatment of bone diseases
UA120075C2 (uk) Фармацевтична композиція для лікування запальних змін прямої кишки
MX2019000136A (es) Composiciones de acido cromoglicico para tratamiento de dermatitis.
GB201720101D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MX2021000475A (es) Isoxazol como agonista del receptor fxr.